Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06045091
Other study ID # HRAIN01-MM04-POC
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date July 4, 2023
Est. completion date September 30, 2027

Study information

Verified date September 2023
Source Hrain Biotechnology Co., Ltd.
Contact Xuedong Sun, Doctor
Phone +8615811287219
Email sunxuedong@dashengbio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of human BCMA targeted CAR-NK Cells injection, and to preliminarily observe the efficacy of the trial drug in patients with relapsed/refractory multiple myeloma or plasma cell leukemia.


Description:

Subjects with relapsed/refractory multiple myeloma or plasma cell leukemia can participate if all eligibility criteria are met. Tests required to determine eligibility including disease assessments, a physical exam, Electrocardiograph, Computed tomography (CT)/Magnetic Resonance Imaging (MRI)/Positron Emission Tomography (PET), liver/renal function tests, complete blood count with differential and complete metabolic profile and etc. Subjects will receive preconditioning chemotherapy prior to the first infusion of human BCMA targeted CAR-NK Cells injection. After the infusion, subjects will be followed for adverse events, pharmacokinetic/pharmacodynamics characteristics, efficacy of human BCMA targeted CAR-NK cells. Study procedures may be performed while hospitalized.


Recruitment information / eligibility

Status Recruiting
Enrollment 18
Est. completion date September 30, 2027
Est. primary completion date September 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:Subjects must meet all of the following criteria to be enrolled: - Subjects volunteer to participate in clinical trials, understand and sign the informed consent document, be willing to complete all the trial procedures; - 18 years and older, Male and female; - Expected survival > 12 weeks; - Documented evidence of multiple myeloma at diagnosis as defined by IMWG updated criteria (2014), or plasma cell leukemia at diagnosis as defined by Diagnosis and therapeutic criteria of hematologic disease (4th edition); - One of the following indicators is satisfied: 1. Serum M protein: IgG M protein =5 g/L; or IgA M protein =5 g/L; or IgD M protein and IgD >ULN; 2. Urine M protein =200 mg/24h; 3. Affected serum free light chain =100 mg/L and Serum free light chain ratio is abnormal; 4. Clonal bone marrow plasma cells =10 % for non-secretory myeloma; - Patients with relapsed/refractory multiple myeloma or plasma cell leukemia, satisfying: 1. Patients have received at least 3 prior MM or PCL treatment regimens containing at least one proteasome inhibitor and one immunomodulatory; 2. Progress is documented within 60 days of the most recent anti-tumor treatment, or efficacy assessment does not reach minimal response(MR) or above; - Liver, kidney and cardiopulmonary functions meet the following requirements: 1. Creatinine clearance rate (estimated by CockcroftGault formula) =30mL/min; 2. Left ventricular ejection fraction > 50%; 3. Baseline peripheral oxygen saturation > 95%; 4. Total bilirubin= 2×ULN; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5×ULN; - Blood routine examination satisfying hemoglobin=60 g/L, neutrophils= 1.0×10^9/L, and platelets=30×10^9/L, can complete this trial according to the judgement of investigators. Exclusion Criteria:Any one of the following conditions cannot be selected as a subject: - Accompanied by other uncontrolled malignancies; - Subjects with positive Hepatitis B surface antigen(HBsAg) or Hepatitis B core antibody (HBcAb) and hepatitis B virus (HBV) DNA titers higher than the lower limit of the normal range of the investigative site; Hepatitis C virus (HCV) antibody positive and peripheral blood HCV RNA positive; Human Immunodeficiency Viral (HIV) antibody positive; syphilis primary screening antibody positive; - Any instability of systemic disease, including but not limited to unstable angina, cerebrovascular accident, or transient cerebral ischemic (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure (New York heart association (NYHA) classification = III), need drug therapy of severe arrhythmia, liver, kidney, or metabolic disease; - Subjects who are considered unsuitable to participate in this trial by the investigator. - Pregnant or lactating woman, and female subject who plans to have a pregnancy within 1 year after cell transfusion, or male subject whose partner plans to have a pregnancy within 1 year after cell transfusion; - Received CAR-NK treatment or other gene therapies before enrollment; - Subjects who have a disease that affects the signing of written informed consent or who are unable to comply with research procedures; or who are unwilling or unable to comply with research requirements; - Subjects who have had severe immediate hypersensitivity reactions to any drugs used in this research; - Active or uncontrollable infection requiring systemic therapy within 14 days prior to enrollment; - In the past two years, the terminal organ was damaged due to autoimmune diseases (such as Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus), or the systemic use of immunosuppressive or other systemic disease control drugs was required; - Patients with symptoms of central nervous system.

Study Design


Intervention

Drug:
Human BCMA targeted CAR-NK cells injection
Allogenic genetically modified anti-BCMA CAR transduced NK cells

Locations

Country Name City State
China Shanghai Changzheng Hospital Shanghai Shanghai

Sponsors (2)

Lead Sponsor Collaborator
Hrain Biotechnology Co., Ltd. Shanghai Changzheng Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose limited toxicity (DLT) Safety Indicators 28 days post infusion
Secondary Pharmacokinetics parameters - the highest concentration of human BCMA targeted CAR-NK cells amplified in peripheral blood and bone marrow after infusion Effectiveness Metrics 2 years post infusion
Secondary Pharmacokinetics parameters - the time to reach the highest concentration of human BCMA targeted CAR-NK cells amplified in peripheral blood and bone marrow after infusion Effectiveness Metrics 2 years post infusion
Secondary Pharmacokinetics parameters - the 28-day area under the curve of human BCMA targeted CAR-NK cells amplified in peripheral blood and bone marrow after infusion Effectiveness Metrics 2 years post infusion
Secondary Pharmacodynamics characteristics - the detection values of CRP, IL-6, IL-15, Granzyme B cytokines in peripheral blood Effectiveness Metrics 2 years post infusion
Secondary Pharmacodynamics characteristics - the detection values of monoclonal plasma cell in bone marrow Effectiveness Metrics 2 years post infusion
Secondary Overall response rate (ORR, include PR, VGPR, CR and sCR) after administration Effectiveness Metrics 3 months post infusion
Secondary Percentage of subjects with negative minimal residual disease (MRD) Effectiveness Metrics 2 years post infusion
Secondary Duration of subjects with negative minimal residual disease (MRD) Effectiveness Metrics 2 years post infusion
Secondary Number of subjects with adverse events Safety Metrics 2 years post infusion
Secondary Change from baseline in perform status as measured by Easten Cooperative Oncology Group (ECOG) score 2 years post infusion Safety Metrics
Secondary The occurrence rate of adverse events grade=3 assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Safety Metrics 2 years post infusion
Secondary Change in body weight over time after infusion Safety Metrics 2 years post infusion
Secondary Duration of remission (DOR) after administration Effectiveness Metrics 2 years post infusion
Secondary Overall Survival (OS) after administration Effectiveness Metrics 2 years post infusion
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1